IPL for melasma: read the trial endpoint and recurrence plan
IPL has been studied for melasma, but small trials of particular light protocols do not make every IPL device a durable melasma treatment. The consultation should identify the diagnosis, exact platform and filter, any accompanying topical care, pigment-risk plan, and how recurrence will be measured.
IPL can be discussed as a selected adjunct for diagnosed melasma, but the supporting trials are small and protocol-specific. They do not establish that every IPL device clears melasma, prevents recurrence, or is preferable for every skin tone. A credible plan names the exact light settings and co-treatments, measures a defined pigment outcome, and specifies what happens if pigment rebounds.123
This is an evidence-reading question rather than a general melasma primer. The South Florida melasma guide covers diagnosis, light protection and the wider treatment sequence. Here the decision begins when a clinic specifically offers an IPL package for a confirmed melasma pattern.
Read what the IPL study actually compared
One randomized study of 20 participants compared specific low-fluence, short-pulse IPL approaches and measured modified Melasma Area and Severity Index changes over a short study window.2 A separate 30-person split-face study in Asian women compared fractionated and conventional IPL schedules; the conventional side rebounded during the treatment course in that study.3 These findings show that delivery details and time point matter. They cannot establish that another machine, filter, skin type, topical regimen, or maintenance schedule has the same result.
| Trial detail | Question for an advertised IPL plan |
|---|---|
| Participants and pigment pattern | Does the study population resemble the person and diagnosed melasma pattern? |
| Device and delivery | Is the exact platform, filter and protocol the one studied? |
| Concurrent treatment | What topical care or light protection occurred alongside IPL? |
| Outcome | Was improvement a standardized severity score, photographs, patient rating or a different measure? |
| Follow-up | Was rebound measured after the treatment course ended? |
If several treatments changed at once, an improvement cannot be assigned entirely to the IPL machine. If a photograph was taken soon after a session, it may miss delayed darkening or recurrence. A lower energy description alone is not a patient-specific safety guarantee.
A melasma clearance is a device claim, not a durability result
FDA K252753 includes melasma in the indications for specified IPL filter configurations.4 That is a real, device-specific clearance, not a blanket statement about every IPL platform. Nor is it an FDA diagnosis of a person’s brown patch or proof of durable benefit for that person. IPL for sun spots handles the separate lentigo decision. The two pigment conditions can look similar in marketing images but require different evidence and expectations.
Ask the practice for its exact device model and filter, the melasma line of the record it cites, and the trial or clinical rationale for the proposed protocol. A brand logo, a general “FDA cleared” badge, and a randomized paper about another setup are not interchangeable records.
Treat recurrence as an endpoint, not a surprise
AAD describes melasma as a condition needing ongoing, individualized care; procedures may be used in a broader plan.1 A South Florida IPL quote should explain how baseline light exposure, topical care, irritation, and follow-up will be handled between and after sessions. This is not a promise that a particular sunscreen or protocol will prevent recurrence. It is a request to define how recurrence would be recognized and what the clinician would reassess.
Before buying a series, request standardized baseline and later photographs, an agreed pigment scale or other meaningful measure, the planned time points after the final session, and a response plan for worsening pigmentation. The IPL provider hub is a starting point for consultations; choose the plan that can account for the exact device and the long-term pigment question.
Sources
- American Academy of Dermatology. Melasma: diagnosis and treatment. Melasma requires a diagnosis and ongoing care; procedural light treatments are adjuncts rather than universal cures. Accessed .
- PubMed. Effectiveness of low-fluence and short-pulse intense pulsed light in melasma: a randomized study. Original small randomized IPL study measuring a melasma severity index under defined settings and short follow-up. Accessed .
- PubMed. Split-face randomized fractionated versus conventional IPL study in melasma. Original 30-person Asian-women study shows protocol-specific change and rebound during one arm's course; not a universal long-term result. Accessed .
- U.S. Food and Drug Administration. 510(k) K252753, Vydence Family of Lasers. Named IPL configurations include melasma among their cleared indications; clearance does not establish a person's diagnosis, durable response, or claims for other devices. Accessed .